Literature DB >> 17827720

Enhanced expression of membrane-associated sialidase Neu3 decreases GD3 and increases GM3 on the surface of Jurkat cells during etoposide-induced apoptosis.

Yutaro Azuma1, Hirotaka Sato, Koji Higai, Kojiro Matsumoto.   

Abstract

We previously reported that, in Jurkat human T cells, the topoisomerase II inhibitor etoposide enhances sialidase activity and reduces cell surface sialic acid levels at an early stage of apoptosis and that the decreases in sialic acid are suppressed by the sialidase inhibitor 2,3-dehydro-2-deoxy-N-acetylneuraminic acid [Azuma Y., et al., Glycoconj. J., 17, 301-306 (2000)]. In the current studies, we treated Jurkat cells with etoposide and examined the changes in the cell surface levels of gangliosides GM1, GM2, GM3, GD1a, and GD3 at physiological pH using anti-ganglioside antibodies. We also examined the sialidase activity on the cell surface using 4-methylumbelliferyl N-acetylneuraminic acid and measured the mRNA expression of the plasma membrane-associated sialidase Neu3 and the lysozomal Neu1 using real-time PCR. We found an increase in GM3 and a decrease in GD3 during the early stage (4 h) of etoposide-induced apoptosis that preceded the increase in cell surface exposure of phosphatidylserine (4 to 6 h). The caspase 3 inhibitor acetyl-Asp-Glu-Val-Asp-aldehyde significantly suppressed changes in GM3 and GD3 and blocked the enhanced cell surface sialidase activity. Furthermore, etoposide caused a gradual up-regulation of Neu3 mRNA expression but not Neu1 mRNA expression. Enhanced Neu3 mRNA expression was suppressed in the presence of caspase 3 inhibitor. These results indicate that Neu3 is up-regulated in Jurkat cells undergoing etoposide-induced apoptosis through intracellular signaling events downstream of caspase 3 activation and that enhanced Neu3 activity is closely related to the changes of cell surface ganglioside composition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17827720     DOI: 10.1248/bpb.30.1680

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  Macrophages discriminate glycosylation patterns of apoptotic cell-derived microparticles.

Authors:  Rostyslav O Bilyy; Tanya Shkandina; Andriy Tomin; Luis E Muñoz; Sandra Franz; Volodymyr Antonyuk; Yuriy Ya Kit; Matthias Zirngibl; Barbara G Fürnrohr; Christina Janko; Kirsten Lauber; Martin Schiller; Georg Schett; Rostyslav S Stoika; Martin Herrmann
Journal:  J Biol Chem       Date:  2011-11-10       Impact factor: 5.157

2.  Rapid Trimming of Cell Surface Polysialic Acid (PolySia) by Exovesicular Sialidase Triggers Release of Preexisting Surface Neurotrophin.

Authors:  Mizuki Sumida; Masaya Hane; Uichiro Yabe; Yasushi Shimoda; Oliver M T Pearce; Makoto Kiso; Taeko Miyagi; Makoto Sawada; Ajit Varki; Ken Kitajima; Chihiro Sato
Journal:  J Biol Chem       Date:  2015-03-06       Impact factor: 5.157

3.  Effects of differential glycosylation of glycodelins on lymphocyte survival.

Authors:  Cheuk-Lun Lee; Poh-Choo Pang; William S B Yeung; Bérangère Tissot; Maria Panico; Terence T H Lao; Ivan K Chu; Kai-Fai Lee; Man-Kin Chung; Kevin K W Lam; Riitta Koistinen; Hannu Koistinen; Markku Seppälä; Howard R Morris; Anne Dell; Philip C N Chiu
Journal:  J Biol Chem       Date:  2009-02-24       Impact factor: 5.157

4.  VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.

Authors:  Irina V Tiper; Sarah M Temkin; Sarah Spiegel; Simeon E Goldblum; Robert L Giuntoli; Mathias Oelke; Jonathan P Schneck; Tonya J Webb
Journal:  Clin Cancer Res       Date:  2016-04-13       Impact factor: 12.531

5.  Mammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond.

Authors:  Erik P Lillehoj; Irina G Luzina; Sergei P Atamas
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

Review 6.  Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis.

Authors:  Fiona Haxho; Ronald J Neufeld; Myron R Szewczuk
Journal:  Oncotarget       Date:  2016-06-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.